Revance Therapeutics, Inc. 1.75% 15-FEB-2027Revance Therapeutics, Inc. 1.75% 15-FEB-2027Revance Therapeutics, Inc. 1.75% 15-FEB-2027

Revance Therapeutics, Inc. 1.75% 15-FEB-2027

No trades
See on Supercharts

RVNC5133129 analysis



Key facts


Issue date
Feb 17, 2021
Maturity date
Feb 15, 2027
Outstanding amount
‪287.50 M‬USD
Face value
1,000.00USD
Minimum denomination
1,000.00USD
Coupon
1.75% (Fixed)
Yield to maturity
9.41%
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Go deeper with bond data
Access the most important data for bonds including coupon rates, issue ratings, redemption data and more.